Quick Answer
AtriCure, Inc. reported Cash and Equivalents of $167.43 million for fiscal year 2025.
AtriCure, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $167.43M | +36.4% |
| 2024 | $122.72M | +45.6% |
| 2023 | $84.31M | +45.1% |
| 2022 | $58.10M | +33.1% |
| 2021 | $43.65M | +4.1% |
| 2020 | $41.94M | +47.3% |
| 2019 | $28.48M | -11.6% |
| 2018 | $32.23M | +47.8% |
| 2017 | $21.81M | -9.9% |
| 2016 | $24.21M | +1.9% |
| 2015 | $23.76M | -16.3% |
| 2014 | $28.38M | +90.6% |
| 2013 | $14.89M | +92.1% |
| 2012 | $7.75M | -20.6% |
| 2011 | $9.76M | +130.7% |
| 2010 | $4.23M | -52.5% |
| 2009 | $8.90M | -22.2% |
| 2008 | $11.45M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $147.87M | +13.4% | +25.5% |
| June 30, 2025 | $117.80M | +11.1% | +17.9% |
| March 31, 2025 | $99.89M | +53.7% | -18.6% |
| December 31, 2024 | $122.72M | +45.6% | -5.8% |
| September 30, 2024 | $130.34M | +61.7% | +22.9% |
| June 30, 2024 | $106.03M | +57.7% | +63.2% |
| March 31, 2024 | $64.97M | -16.0% | -22.9% |
| December 31, 2023 | $84.31M | +45.1% | +4.6% |
- AtriCure, Inc. showed an increase of +36.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, AtriCure, Inc.’s cash and equivalents has grown by 1362.5% (from $11.45 million to $167.43 million).
- The most recent figure is from AtriCure, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: